Tejaswini Baral, Pravachana Malakapogu, Zuha Shyma, Shilia Jacob Kurian, Ruby Benson, Mohan K Manu, Debasis Bagchi, Sonal Sekhar Miraj
{"title":"Efficacy of iron replacement in pulmonary hypertension: A systematic review.","authors":"Tejaswini Baral, Pravachana Malakapogu, Zuha Shyma, Shilia Jacob Kurian, Ruby Benson, Mohan K Manu, Debasis Bagchi, Sonal Sekhar Miraj","doi":"10.1177/02601060241303814","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> The systematic review summarizes the current evidence on the efficacy and safety of iron replacement in patients with pulmonary hypertension (PH). <b>Methods:</b> A systematic literature search was conducted in electronic databases like PubMed, Scopus, Web of Science, and Embase up to April 2024. Eligible studies investigating iron replacement therapy in pulmonary hypertension patients were included in the review. Quality assessment of included studies was performed using standardized risk of bias tools. <b>Results:</b> Five studies met the study-eligible criteria and were included for review. Out of all final selected five studies, one was a randomized control trial (RCT), two were non-RCT, and two were observational studies. We observed an improvement in the six-minute walk distance (6MWD) test, iron indices, peak oxygen intake, and anaerobic threshold after the iron replacement. In all included studies, the iron replacement was tolerated well with no serious adverse events. <b>Conclusion:</b> Regardless of the variation in the study design, positive effects were observed on multiple outcome measures like the 6MWD test, cardiopulmonary exercise test parameter, and iron indices upon iron replacement in PH patients with iron deficiency. Further controlled trials are needed to enable better treatment group comparisons. Exploring long-term impacts on comorbidities, mortality, and disease progression would provide valuable insights for managing pulmonary hypertension.</p>","PeriodicalId":19352,"journal":{"name":"Nutrition and health","volume":" ","pages":"2601060241303814"},"PeriodicalIF":1.9000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition and health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02601060241303814","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: The systematic review summarizes the current evidence on the efficacy and safety of iron replacement in patients with pulmonary hypertension (PH). Methods: A systematic literature search was conducted in electronic databases like PubMed, Scopus, Web of Science, and Embase up to April 2024. Eligible studies investigating iron replacement therapy in pulmonary hypertension patients were included in the review. Quality assessment of included studies was performed using standardized risk of bias tools. Results: Five studies met the study-eligible criteria and were included for review. Out of all final selected five studies, one was a randomized control trial (RCT), two were non-RCT, and two were observational studies. We observed an improvement in the six-minute walk distance (6MWD) test, iron indices, peak oxygen intake, and anaerobic threshold after the iron replacement. In all included studies, the iron replacement was tolerated well with no serious adverse events. Conclusion: Regardless of the variation in the study design, positive effects were observed on multiple outcome measures like the 6MWD test, cardiopulmonary exercise test parameter, and iron indices upon iron replacement in PH patients with iron deficiency. Further controlled trials are needed to enable better treatment group comparisons. Exploring long-term impacts on comorbidities, mortality, and disease progression would provide valuable insights for managing pulmonary hypertension.
目的:系统综述目前关于肺动脉高压(PH)患者铁替代的有效性和安全性的证据。方法:系统检索PubMed、Scopus、Web of Science、Embase等电子数据库至2024年4月的文献。本综述纳入了研究肺动脉高压患者铁替代治疗的符合条件的研究。采用标准化偏倚风险工具对纳入研究进行质量评估。结果:有5项研究符合研究标准,并被纳入回顾。在最终选定的5项研究中,1项为随机对照试验(RCT), 2项为非随机对照试验,2项为观察性研究。我们观察到补铁后6分钟步行距离(6MWD)测试、铁指标、峰值摄氧量和无氧阈值的改善。在所有纳入的研究中,铁替代品的耐受性良好,没有严重的不良事件。结论:无论研究设计如何变化,在PH缺铁患者补铁后,6MWD试验、心肺运动试验参数、铁指标等多项指标均有积极影响。需要进一步的对照试验来进行更好的治疗组比较。探索对合并症、死亡率和疾病进展的长期影响将为管理肺动脉高压提供有价值的见解。